Chemistry:Selective serotonin reuptake inhibitor
|Selective serotonin reuptake inhibitor|
Serotonin, the neurotransmitter that is involved in the mechanism of action of SSRIs.
|Synonyms||Serotonin-specific reuptake inhibitors, serotonergic antidepressants|
|Use||Major depressive disorder, anxiety disorders|
|Biological target||Serotonin transporter|
|Consumer Reports||Best Buy Drugs|
Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.
SSRIs increase the extracellular level of the neurotransmitter serotonin by limiting its reabsorption (reuptake) into the presynaptic cell. They have varying degrees of selectivity for the other monoamine transporters, with pure SSRIs having strong affinity for the serotonin transporter and only weak affinity for the norepinephrine and dopamine transporters.
SSRIs are the most widely prescribed antidepressants in many countries. The efficacy of SSRIs in mild or moderate cases of depression has been disputed and may or may not be outweighed by side effects, especially in adolescent populations.
The main indication for SSRIs is major depressive disorder; however, they are frequently prescribed for anxiety disorders, such as social anxiety disorder, generalized anxiety disorder, panic disorder, obsessive–compulsive disorder (OCD), eating disorders, chronic pain, and, in some cases, for posttraumatic stress disorder (PTSD). They are also frequently used to treat depersonalization disorder, although with varying results.
Antidepressants are recommended by the UK National Institute for Health and Care Excellence (NICE) as a first-line treatment of severe depression and for the treatment of mild-to-moderate depression that persists after conservative measures such as cognitive therapy. They recommend against their routine use by those who have chronic health problems and mild depression.
There has been controversy regarding the efficacy of SSRIs in treating depression depending on its severity and duration.
- Two meta-analyses published in 2008 (Kirsch) and 2010 (Fournier) found that in mild and moderate depression, the effect of SSRIs is small or none compared to placebo, while in very severe depression the effect of SSRIs is between "relatively small" and "substantial". The 2008 meta-analysis combined 35 clinical trials submitted to the Food and Drug Administration (FDA) before licensing of four newer antidepressants (including the SSRIs paroxetine and fluoxetine, the non-SSRI antidepressant nefazodone, and the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine). The authors attributed the relationship between severity and efficacy to a reduction of the placebo effect in severely depressed patients, rather than an increase in the effect of the medication. Some researchers have questioned the statistical basis of this study suggesting that it underestimates the effect size of antidepressants.
- A 2012 meta-analysis of fluoxetine and venlafaxine concluded that statistically and clinically significant treatment effects were observed for each drug relative to placebo irrespective of baseline depression severity; some of the authors however disclosed substantial relationships with pharmaceutical industries.
- A 2017 systematic review stated that "SSRIs versus placebo seem to have statistically significant effects on depressive symptoms, but the clinical significance of these effects seems questionable and all trials were at high risk of bias. Furthermore, SSRIs versus placebo significantly increase the risk of both serious and non-serious adverse events. Our results show that the harmful effects of SSRIs versus placebo for major depressive disorder seem to outweigh any potentially small beneficial effects". Fredrik Hieronymus et al. criticized the review as inaccurate and misleading, but they also disclosed multiple ties to pharmaceutical industries and receipt of speaker's fees.
In 2018, a systematic review and network meta-analysis comparing the efficacy and acceptability of 21 antidepressant drugs showed escitalopram to be one of the most effective.
The use of SSRIs in children with depression remains controversial. A 2021 Cochrane review concluded that, for children and adolescents, SSRIs "may reduce depression symptoms in a small and unimportant way compared with placebo." However, it also noted significant methodological limitations that make drawing definitive conclusions about efficacy difficult. Fluoxetine is the only SSRI authorized for use in children and adolescents with moderate to severe depression in the United Kingdom .
Social anxiety disorder
Some SSRIs are effective for social anxiety disorder, although their effects on symptoms is not always robust and their use is sometimes rejected in favor of psychological therapies. Paroxetine was the first drug to be approved for social anxiety disorder and it is considered effective for this disorder, sertraline and fluvoxamine were later approved for it, too, escitalopram and citalopram are used off label with acceptable efficacy, while fluoxetine is not considered to be effective for this disorder.
Post-traumatic stress disorder
PTSD is relatively hard to treat and generally treatment is not highly effective; SSRIs are no exception. They are not very effective for this disorder and only two SSRI are FDA approved for this condition, paroxetine and sertraline. Paroxetine has slightly higher response and remission rates for PTSD than sertraline, but both are not fully effective for many patients. Fluoxetine is used off label, but with mixed results; venlafaxine, an SNRI, is considered somewhat effective, although used off label, too. Fluvoxamine, escitalopram and citalopram are not well tested in this disorder. Paroxetine remains the most suitable drug for PTSD as of now, but with limited benefits.
Generalized anxiety disorder
SSRIs are recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of generalized anxiety disorder (GAD) that has failed to respond to conservative measures such as education and self-help activities. GAD is a common disorder of which the central feature is excessive worry about a number of different events. Key symptoms include excessive anxiety about multiple events and issues, and difficulty controlling worrisome thoughts that persists for at least 6 months.
Antidepressants provide a modest-to-moderate reduction in anxiety in GAD, and are superior to placebo in treating GAD. The efficacy of different antidepressants is similar.
In Canada, SSRIs are a first-line treatment of adult obsessive–compulsive disorder (OCD). In the UK, they are first-line treatment only with moderate to severe functional impairment and as second line treatment for those with mild impairment, though, as of early 2019, this recommendation is being reviewed. In children, SSRIs can be considered a second line therapy in those with moderate-to-severe impairment, with close monitoring for psychiatric adverse effects. SSRIs, especially fluvoxamine, which is the first one to be FDA approved for OCD, are efficacious in its treatment; patients treated with SSRIs are about twice as likely to respond to treatment as those treated with placebo. Efficacy has been demonstrated both in short-term treatment trials of 6 to 24 weeks and in discontinuation trials of 28 to 52 weeks duration.
Paroxetine CR was superior to placebo on the primary outcome measure. In a 10-wk randomized controlled, double-blind trial escitalopram was more effective than placebo. Fluvoxamine, another SSRI, has shown positive results. However, evidence for their effectiveness and acceptability is unclear.
Antidepressants are recommended as an alternative or additional first step to self-help programs in the treatment of bulimia nervosa. SSRIs (fluoxetine in particular) are preferred over other anti-depressants due to their acceptability, tolerability, and superior reduction of symptoms in short-term trials. Long-term efficacy remains poorly characterized.
Similar recommendations apply to binge eating disorder. SSRIs provide short-term reductions in binge eating behavior, but have not been associated with significant weight loss.
Clinical trials have generated mostly negative results for the use of SSRIs in the treatment of anorexia nervosa. Treatment guidelines from the National Institute of Health and Clinical Excellence recommend against the use of SSRIs in this disorder. Those from the American Psychiatric Association note that SSRIs confer no advantage regarding weight gain, but that they may be used for the treatment of co-existing depressive, anxiety, or OCD.
SSRIs have been used off-label in the treatment of stroke patients, including those with and without symptoms of depression. A 2019 meta-analysis of randomized, controlled clinical trials found a statistically significant effect of SSRIs on dependence, neurological deficit, depression, and anxiety but the studies had a high risk of bias. No reliable evidence points to their routine use to promote recovery following stroke. Thrombosis risk is reduced because SSRIs limit serotonin availability to platelets, so benefits, such as stroke recovery, of reduced clotting go up, with SSRIs.
SSRIs are effective for the treatment of premature ejaculation. Taking SSRIs on a chronic, daily basis is more effective than taking them prior to sexual activity. The increased efficacy of treatment when taking SSRIs on a daily basis is consistent with clinical observations that the therapeutic effects of SSRIs generally take several weeks to emerge. Sexual dysfunction ranging from decreased libido to anorgasmia is usually considered to be a significantly distressing side effect which may lead to noncompliance in patients receiving SSRIs. However, for those with premature ejaculation, this very same side effect becomes the desired effect.
SSRIs such as sertraline have been found to be effective in decreasing anger.
Side effects vary among the individual drugs of this class and may include:
- increased risk of bone fractures
- suicidal ideation (thoughts of suicide) and other risks (see below)
SSRIs can cause various types of sexual dysfunction such as anorgasmia, erectile dysfunction, diminished libido, genital numbness, and sexual anhedonia (pleasureless orgasm). Sexual problems are common with SSRIs. While initial trials showed side effects in 5-15% of users (based on spontaneous reporting by users), later studies (based on asking patients directly) have shown side effect rates from 36% to 98%. Poor sexual function is also one of the most common reasons people stop the medication.
In some cases, symptoms of sexual dysfunction may persist after discontinuation of SSRIs.:14 This combination of symptoms is sometimes referred to as Post-SSRI Sexual Dysfunction (PSSD). On the 11th of June 2019 the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency concluded that a possible relationship exists between SSRI use and persistent sexual dysfunction after cessation of use. The committee concluded that a warning should be added to the label of SSRIs and SNRIs regarding this possible risk.
The mechanism by which SSRIs may cause sexual side effects is not well understood (As of 2021). The range of possible mechanisms includes (1) nonspecific neurological effects (e.g., sedation) that globally impair behavior including sexual function; (2) specific effects on brain systems mediating sexual function; (3) specific effects on peripheral tissues and organs, such as the penis, that mediate sexual function; and (4) direct or indirect effects on hormones mediating sexual function. Management strategies include: for erectile dysfunction the addition of a PDE5 inhibitor such as sildenafil; for decreased libido, possibly adding or switching to bupropion; and for overall sexual dysfunction, switching to nefazodone.
A number of non-SSRI drugs are not associated with sexual side effects (such as bupropion, mirtazapine, tianeptine, agomelatine and moclobemide).
Several studies have suggested that SSRIs may adversely affect semen quality.
While trazodone (an antidepressant with alpha adrenergic receptor blockade) is a notorious cause of priapism, cases of priapism have also been reported with certain SSRIs (e.g. fluoxetine, citalopram).
Certain antidepressants may cause emotional blunting, characterized by reduced intensity of both positive and negative emotions as well as symptoms of apathy, indifference, and amotivation. It may be experienced as either beneficial or detrimental depending on the situation. This side effect has been particularly associated with serotonergic antidepressants like SSRIs and SNRIs, but may be less with atypical antidepressants like bupropion, agomelatine, and vortioxetine. Higher doses of antidepressants seem to be more likely to produce emotional blunting than lower doses. It can be decreased by reducing dosage, discontinuing the medication, or switching to a different antidepressant that may have less propensity for causing this side effect.
Researcher David Healy and others have reviewed available data, concluding that SSRIs increase violent acts, in adults and children, both on therapy and during withdrawal. This view is also shared by some patient activist groups.
Acute narrow-angle glaucoma is the most common and important ocular side effect of SSRIs, and often goes misdiagnosed.
SSRIs do not appear to affect the risk of coronary heart disease (CHD) in those without a previous diagnosis of CHD. A large cohort study suggested no substantial increase in the risk of cardiac malformations attributable to SSRI usage during the first trimester of pregnancy. A number of large studies of people without known pre-existing heart disease have reported no EKG changes related to SSRI use. The recommended maximum daily dose of citalopram and escitalopram was reduced due to concerns with QT prolongation. In overdose, fluoxetine has been reported to cause sinus tachycardia, myocardial infarction, junctional rhythms and trigeminy. Some authors have suggested electrocardiographic monitoring in patients with severe pre-existing cardiovascular disease who are taking SSRIs.
SSRIs directly increase the risk of abnormal bleeding by lowering platelet serotonin levels, which are essential to platelet-driven hemostasis. SSRIs interact with anticoagulants, like warfarin, and antiplatelet drugs, like aspirin. This includes an increased risk of GI bleeding, and post operative bleeding. The relative risk of intracranial bleeding is increased, but the absolute risk is very low. SSRIs are known to cause platelet dysfunction. This risk is greater in those who are also on anticoagulants, antiplatelet agents and NSAIDs (nonsteroidal anti-inflammatory drugs), as well as with the co-existence of underlying diseases such as cirrhosis of the liver or liver failure.
Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests an association between SSRI usage at therapeutic doses and a decrease in bone mineral density, as well as increased fracture risk, a relationship that appears to persist even with adjuvant bisphosphonate therapy. However, because the relationship between SSRIs and fractures is based on observational data as opposed to prospective trials, the phenomenon is not definitively causal. There also appears to be an increase in fracture-inducing falls with SSRI use, suggesting the need for increased attention to fall risk in elderly patients using the medication. The loss of bone density does not appear to occur in younger patients taking SSRIs.
SSRI and SNRI antidepressants may cause jaw pain/jaw spasm reversible syndrome (although it is not common). Buspirone appears to be successful in treating bruxism on SSRI/SNRI induced jaw clenching.
Serotonin syndrome is typically caused by the use of two or more serotonergic drugs, including SSRIs. Serotonin syndrome is a condition that can range from mild (most common) to deadly. Mild symptoms may consist of increased heart rate, fever, shivering, sweating, dilated pupils, myoclonus (intermittent jerking or twitching), as well as hyperreflexia. Concomitant use of SSRIs or SNRIs for depression with a triptan for migraine does not appear to heighten the risk of the serotonin syndrome. Taking monoamine oxidase inhibitors (MAOIs) in combination with SSRIs can be fatal, since MAOIs disrupt monoamine oxidase, an enzyme which is needed to break down serotonin and other neurotransmitters. Without monoamine oxidase, the body is unable to eliminate excess neurotransmitters, allowing them to build up to dangerous levels. The prognosis for recovery in a hospital setting is generally good if serotonin syndrome is correctly identified. Treatment consists of discontinuing any serotonergic drugs and providing supportive care to manage agitation and hyperthermia, usually with benzodiazepines.
Children and adolescents
Meta analyses of short duration randomized clinical trials have found that SSRI use is related to a higher risk of suicidal behavior in children and adolescents. For instance, a 2004 U.S. Food and Drug Administration (FDA) analysis of clinical trials on children with major depressive disorder found statistically significant increases of the risks of "possible suicidal ideation and suicidal behavior" by about 80%, and of agitation and hostility by about 130%. According to the FDA, the heightened risk of suicidality is within the first one to two months of treatment. The National Institute for Health and Care Excellence (NICE) places the excess risk in the "early stages of treatment". The European Psychiatric Association places the excess risk in the first two weeks of treatment and, based on a combination of epidemiological, prospective cohort, medical claims, and randomized clinical trial data, concludes that a protective effect dominates after this early period. A 2014 Cochrane review found that at six to nine months, suicidal ideation remained higher in children treated with antidepressants compared to those treated with psychological therapy.
A recent comparison of aggression and hostility occurring during treatment with fluoxetine to placebo in children and adolescents found that no significant difference between the fluoxetine group and a placebo group. There is also evidence that higher rates of SSRI prescriptions are associated with lower rates of suicide in children, though since the evidence is correlational, the true nature of the relationship is unclear.
In 2004, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom judged fluoxetine (Prozac) to be the only antidepressant that offered a favorable risk-benefit ratio in children with depression, though it was also associated with a slight increase in the risk of self-harm and suicidal ideation. Only two SSRIs are licensed for use with children in the UK, sertraline (Zoloft) and fluvoxamine (Luvox), and only for the treatment of obsessive–compulsive disorder. Fluoxetine is not licensed for this use.
It is unclear whether SSRIs affect the risk of suicidal behavior in adults.
- A 2005 meta-analysis of drug company data found no evidence that SSRIs increased the risk of suicide; however, important protective or hazardous effects could not be excluded.
- A 2005 review observed that suicide attempts are increased in those who use SSRIs as compared to placebo and compared to therapeutic interventions other than tricyclic antidepressants. No difference risk of suicide attempts was detected between SSRIs versus tricyclic antidepressants.
- On the other hand, a 2006 review suggests that the widespread use of antidepressants in the new "SSRI-era" appears to have led to a highly significant decline in suicide rates in most countries with traditionally high baseline suicide rates. The decline is particularly striking for women who, compared with men, seek more help for depression. Recent clinical data on large samples in the US too have revealed a protective effect of antidepressant against suicide.
- A 2006 meta-analysis of random controlled trials suggests that SSRIs increase suicide ideation compared with placebo. However, the observational studies suggest that SSRIs did not increase suicide risk more than older antidepressants. The researchers stated that if SSRIs increase suicide risk in some patients, the number of additional deaths is very small because ecological studies have generally found that suicide mortality has declined (or at least not increased) as SSRI use has increased.
- An additional meta-analysis by the FDA in 2006 found an age-related effect of SSRI's. Among adults younger than 25 years, results indicated that there was a higher risk for suicidal behavior. For adults between 25 and 64, the effect appears neutral on suicidal behavior but possibly protective for suicidal behavior for adults between the ages of 25 and 64. For adults older than 64, SSRI's seem to reduce the risk of both suicidal behavior.
- In 2016 a study criticized the effects of the FDA Black Box suicide warning inclusion in the prescription. The authors discussed the suicide rates might increase also as a consequence of the warning.
Risk of death
A 2017 meta-analysis found that antidepressants including SSRIs were associated with significantly increased risk of death (+33%) and new cardiovascular complications (+14%) in the general population. Conversely, risks were not greater in people with existing cardiovascular disease.
Pregnancy and breastfeeding
SSRI use in pregnancy has been associated with a variety of risks with varying degrees of proof of causation. As depression is independently associated with negative pregnancy outcomes, determining the extent to which observed associations between antidepressant use and specific adverse outcomes reflects a causative relationship has been difficult in some cases. In other cases, the attribution of adverse outcomes to antidepressant exposure seems fairly clear.
SSRI use in pregnancy is associated with an increased risk of spontaneous abortion of about 1.7-fold. Use is also associated with preterm birth.
A systematic review of the risk of major birth defects in antidepressant-exposed pregnancies found a small increase (3% to 24%) in the risk of major malformations and a risk of cardiovascular birth defects that did not differ from non-exposed pregnancies.  Other studies have found an increased risk of cardiovascular birth defects among depressed mothers not undergoing SSRI treatment, suggesting the possibility of ascertainment bias, e.g. that worried mothers may pursue more aggressive testing of their infants. Another study found no increase in cardiovascular birth defects and a 27% increased risk of major malformations in SSRI exposed pregnancies.
The FDA issued a statement on July 19, 2006, stating nursing mothers on SSRIs must discuss treatment with their physicians. However, the medical literature on the safety of SSRIs has determined that some SSRIs like Sertraline and Paroxetine are considered safe for breastfeeding.
Neonatal abstinence syndrome
Several studies have documented neonatal abstinence syndrome, a syndrome of neurological, gastrointestinal, autonomic, endocrine and/or respiratory symptoms among a large minority of infants with intrauterine exposure. These syndromes are short-lived, but insufficient long-term data is available to determine whether there are long-term effects.
Persistent pulmonary hypertension
Persistent pulmonary hypertension (PPHN) is a serious and life-threatening, but very rare, lung condition that occurs soon after birth of the newborn. Newborn babies with PPHN have high pressure in their lung blood vessels and are not able to get enough oxygen into their bloodstream. About 1 to 2 babies per 1000 babies born in the U.S. develop PPHN shortly after birth, and often they need intensive medical care. It is associated with about a 25% risk of significant long-term neurological deficits. A 2014 meta analysis found no increased risk of persistent pulmonary hypertension associated with exposure to SSRI's in early pregnancy and a slight increase in risk associates with exposure late in pregnancy; "an estimated 286 to 351 women would need to be treated with an SSRI in late pregnancy to result in an average of one additional case of persistent pulmonary hypertension of the newborn". A review published in 2012 reached conclusions very similar to those of the 2014 study.
Neuropsychiatric effects in offspring
According to a 2015 review available data found that "some signal exists suggesting that antenatal exposure to SSRIs may increase the risk of ASDs (autism spectrum disorders)" even though a large cohort study published in 2013 and a cohort study using data from Finland's national register between the years 1996 and 2010 and published in 2016 found no significant association between SSRI use and autism in offspring. The 2016 Finland study also found no association with ADHD, but did find an association with increased rates of depression diagnoses in early adolescence.
In adults and children with bipolar disorder, SSRIs may cause a bipolar switch from depression into hypomania/mania. When taken with mood stabilizers, the risk of switching is not increased, however when taking SSRI's as a monotherapy, the risk of switching may be twice or three times that of the average. The changes are not often easy to detect and require monitoring by family and mental health professionals. This switch might happen even with no prior (hypo)manic episodes and might therefore not be foreseen by the psychiatrist.
The following drugs may precipitate serotonin syndrome in people on SSRIs:
- Monoamine oxidase inhibitors (MAOIs) including moclobemide, phenelzine, tranylcypromine, selegiline and methylene blue
- MDMA (ecstasy)
- St. John's wort
- Tricyclic antidepressants (TCAs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Methylene blue
Painkillers of the NSAIDs drug family may interfere and reduce efficiency of SSRIs and may compound the increased risk of gastrointestinal bleeds caused by SSRI use. NSAIDs include:
There are a number of potential pharmacokinetic interactions between the various individual SSRIs and other medications. Most of these arise from the fact that every SSRI has the ability to inhibit certain P450 cytochromes.
0 – no inhibition
+ – mild inhibition
++ – moderate inhibition
+++ – strong inhibition
The CYP2D6 enzyme is entirely responsible for the metabolism of hydrocodone, codeine and dihydrocodeine to their active metabolites (hydromorphone, morphine, and dihydromorphine, respectively), which in turn undergo phase 2 glucuronidation. These opioids (and to a lesser extent oxycodone, tramadol, and methadone) have interaction potential with selective serotonin reuptake inhibitors. The concomitant use of some SSRIs (paroxetine and fluoxetine) with codeine may decrease the plasma concentration of active metabolite morphine, which may result in reduced analgesic efficacy.
Another important interaction of certain SSRIs involves paroxetine, a potent inhibitor of CYP2D6, and tamoxifen, an agent used commonly in the treatment and prevention of breast cancer. Tamoxifen is a prodrug that is metabolised by the hepatic cytochrome P450 enzyme system, especially CYP2D6, to its active metabolites. Concomitant use of paroxetine and tamoxifen in women with breast cancer is associated with a higher risk of death, as much as a 91 percent in women who used it the longest.
SSRIs appear safer in overdose when compared with traditional antidepressants, such as the tricyclic antidepressants. This relative safety is supported both by case series and studies of deaths per numbers of prescriptions. However, case reports of SSRI poisoning have indicated that severe toxicity can occur and deaths have been reported following massive single ingestions, although this is exceedingly uncommon when compared to the tricyclic antidepressants.
Because of the wide therapeutic index of the SSRIs, most patients will have mild or no symptoms following moderate overdoses. The most commonly reported severe effect following SSRI overdose is serotonin syndrome; serotonin toxicity is usually associated with very high overdoses or multiple drug ingestion. Other reported significant effects include coma, seizures, and cardiac toxicity.
Poisoning is also known in animals, and some toxicity information is available for veterinary treatment.
Serotonin reuptake inhibitors should not be abruptly discontinued after extended therapy, and whenever possible, should be tapered over several weeks to minimize discontinuation-related symptoms which may include nausea, headache, dizziness, chills, body aches, paresthesias, insomnia, and brain zaps. Paroxetine may produce discontinuation-related symptoms at a greater rate than other SSRIs, though qualitatively similar effects have been reported for all SSRIs. Discontinuation effects appear to be less for fluoxetine, perhaps owing to its long half-life and the natural tapering effect associated with its slow clearance from the body. One strategy for minimizing SSRI discontinuation symptoms is to switch the patient to fluoxetine and then taper and discontinue the fluoxetine.
Mechanism of action
Serotonin reuptake inhibition
In the brain, messages are passed from a nerve cell to another via a chemical synapse, a small gap between the cells. The presynaptic cell that sends the information releases neurotransmitters including serotonin into that gap. The neurotransmitters are then recognized by receptors on the surface of the recipient postsynaptic cell, which upon this stimulation, in turn, relays the signal. About 10% of the neurotransmitters are lost in this process; the other 90% are released from the receptors and taken up again by monoamine transporters into the sending presynaptic cell, a process called reuptake.
SSRIs inhibit the reuptake of serotonin. As a result, the serotonin stays in the synaptic gap longer than it normally would, and may repeatedly stimulate the receptors of the recipient cell. In the short run, this leads to an increase in signaling across synapses in which serotonin serves as the primary neurotransmitter. On chronic dosing, the increased occupancy of post-synaptic serotonin receptors signals the pre-synaptic neuron to synthesize and release less serotonin. Serotonin levels within the synapse drop, then rise again, ultimately leading to downregulation of post-synaptic serotonin receptors. Other, indirect effects may include increased norepinephrine output, increased neuronal cyclic AMP levels, and increased levels of regulatory factors such as BDNF and CREB. Owing to the lack of a widely accepted comprehensive theory of the biology of mood disorders, there is no widely accepted theory of how these changes lead to the mood-elevating and anti-anxiety effects of SSRIs.
Their effects on serotonin blood levels, which take weeks to take effect, appear to be largely responsible for their slow-to-appear psychiatric effects. SSRIs mediate their action largely with high occupancy in a total of all serotonin transporters within the brain and through this slow downstream changes of large brain regions at therapeutic concentrations, whereas MDMA leads to an excess serotonin release in a short run. This could explain the absence of a "high" by antidepressants and in addition the contrary ability of SSRIs in expressing neuroprotective actions to the neurotoxic abilities of MDMA.
Sigma receptor ligands
|Medication||SERT||σ1||σ2||σ1 / SERT|
|Values are Ki (nM). The smaller the value, the more strongly the|
drug binds to the site.
In addition to their actions as reuptake inhibitors of serotonin, some SSRIs are also, coincidentally, ligands of the sigma receptors. Fluvoxamine is an agonist of the σ1 receptor, while sertraline is an antagonist of the σ1 receptor, and paroxetine does not significantly interact with the σ1 receptor. None of the SSRIs have significant affinity for the σ2 receptor, and the SNRIs, unlike the SSRIs, do not interact with either of the sigma receptors. Fluvoxamine has by far the strongest activity of the SSRIs at the σ1 receptor. High occupancy of the σ1 receptor by clinical dosages of fluvoxamine has been observed in the human brain in positron emission tomography (PET) research. It is thought that agonism of the σ1 receptor by fluvoxamine may have beneficial effects on cognition. In contrast to fluvoxamine, the relevance of the σ1 receptor in the actions of the other SSRIs is uncertain and questionable due to their very low affinity for the receptor relative to the SERT.
The role of inflammation and the immune system in depression has been extensively studied. The evidence supporting this link has been shown in numerous studies over the past ten years. Nationwide studies and meta-analyses of smaller cohort studies have uncovered a correlation between pre-existing inflammatory conditions such as type 1 diabetes, rheumatoid arthritis (RA), or hepatitis, and an increased risk of depression. Data also shows that using pro-inflammatory agents in the treatment of diseases like melanoma can lead to depression. Several meta-analytical studies have found increased levels of proinflammatory cytokines and chemokines in depressed patients. This link has led scientists to investigate the effects of antidepressants on the immune system.
SSRIs were originally invented with the goal of increasing levels of available serotonin in the extracellular spaces. However, the delayed response between when patients first begin SSRI treatment to when they see effects has led scientists to believe that other molecules are involved in the efficacy of these drugs. To investigate the apparent anti-inflammatory effects of SSRIs, both Kohler et al. and Więdłocha et al. conducted meta-analyses which have shown that after antidepressant treatment the levels of cytokines associated with inflammation are decreased. A large cohort study conducted by researchers in the Netherlands investigated the association between depressive disorders, symptoms, and antidepressants with inflammation. The study showed decreased levels of interleukin (IL)-6, a cytokine that has proinflammatory effects, in patients taking SSRIs compared to non-medicated patients.
Treatment with SSRIs has shown reduced production of inflammatory cytokines such as IL-1β, tumor necrosis factor (TNF)-α, IL-6, and interferon (IFN)-γ, which leads to a decrease in inflammation levels and subsequently a decrease in the activation level of the immune response. These inflammatory cytokines have been shown to activate microglia which are specialized macrophages that reside in the brain. Macrophages are a subset of immune cells responsible for host defense in the innate immune system. Macrophages can release cytokines and other chemicals to cause an inflammatory response. Peripheral inflammation can induce an inflammatory response in microglia and can cause neuroinflammation. SSRIs inhibit proinflammatory cytokine production which leads to less activation of microglia and peripheral macrophages. SSRIs not only inhibit the production of these proinflammatory cytokines, they also have been shown to upregulate anti-inflammatory cytokines such as IL-10. Taken together, this reduces the overall inflammatory immune response.
In addition to affecting cytokine production, there is evidence that treatment with SSRIs has effects on the proliferation and viability of immune system cells involved in both innate and adaptive immunity. Evidence shows that SSRIs can inhibit proliferation in T-cells, which are important cells for adaptive immunity and can induce inflammation. SSRIs can also induce apoptosis, programmed cell death, in T-cells. The full mechanism of action for the anti-inflammatory effects of SSRIs is not fully known. However, there is evidence for various pathways to have a hand in the mechanism. One such possible mechanism is the increased levels of cyclic adenosine monophosphate (cAMP) as a result of interference with activation of protein kinase A (PKA), a cAMP dependent protein. Other possible pathways include interference with calcium ion channels, or inducing cell death pathways like MAPK and Notch signaling pathway.
The anti-inflammatory effects of SSRIs have prompted studies of the efficacy of SSRIs in the treatment of autoimmune diseases such as multiple sclerosis, RA, inflammatory bowel diseases, and septic shock. These studies have been performed in animal models but have shown consistent immune regulatory effects. Fluoxetine, an SSRI, has also shown efficacy in animal models of graft vs. host disease. SSRIs have also been used successfully as pain relievers in patients undergoing oncology treatment. The effectiveness of this has been hypothesized to be at least in part due to the anti-inflammatory effects of SSRIs.
Large bodies of research are devoted to using genetic markers to predict whether patients will respond to SSRIs or have side effects that will cause their discontinuation, although these tests are not yet ready for widespread clinical use.
SSRIs are described as 'selective' because they affect only the reuptake pumps responsible for serotonin, as opposed to earlier antidepressants, which affect other monoamine neurotransmitters as well, and as a result, SSRIs have fewer side effects.
There appears to be no significant difference in effectiveness between SSRIs and tricyclic antidepressants, which were the most commonly used class of antidepressants before the development of SSRIs. However, SSRIs have the important advantage that their toxic dose is high, and, therefore, they are much more difficult to use as a means to commit suicide. Further, they have fewer and milder side effects. Tricyclic antidepressants also have a higher risk of serious cardiovascular side effects, which SSRIs lack.
SSRIs act on signal pathways such as cyclic adenosine monophosphate (cAMP) on the postsynaptic neuronal cell, which leads to the release of brain-derived neurotrophic factor (BDNF). BDNF enhances the growth and survival of cortical neurons and synapses.
List of SSRIs
- Citalopram (Celexa)
- Escitalopram (Lexapro)
- Fluoxetine (Prozac)
- Fluvoxamine (Luvox)
- Paroxetine (Paxil)
- Sertraline (Zoloft)
- Dapoxetine (Priligy)
- Indalpine (Upstène)
- Zimelidine (Zelmid)
- Alaproclate (GEA-654)
- Cericlamine (JO-1017)
- Femoxetine (Malexil; FG-4963)
- Ifoxetine (CGP-15210)
- Panuramine (WY-26002)
- Pirandamine (AY-23713)
- Seproxetine ((S)-norfluoxetine)
Although described as SNRIs, duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq) are in fact relatively selective as serotonin reuptake inhibitors (SRIs). They are about at least 10-fold selective for inhibition of serotonin reuptake over norepinephrine reuptake. The selectivity ratios are approximately 1:30 for venlafaxine, 1:10 for duloxetine, and 1:14 for desvenlafaxine. At low doses, these SNRIs act mostly as SSRIs; only at higher doses do they also prominently inhibit norepinephrine reuptake. Milnacipran (Ixel, Savella) and its stereoisomer levomilnacipran (Fetzima) are the only widely marketed SNRIs that inhibit serotonin and norepinephrine to similar degrees, both with ratios close to 1:1.
Vilazodone (Viibryd) and vortioxetine (Trintellix) are SRIs that also act as modulators of serotonin receptors and are described as serotonin modulators and stimulators (SMS). Vilazodone is a 5-HT1A receptor partial agonist while vortioxetine is a 5-HT1A receptor agonist and 5-HT3 and 5-HT7 receptor antagonist. Litoxetine (SL 81–0385) and lubazodone (YM-992, YM-35995) are similar drugs that were never marketed. They are SRIs and litoxetine is also a 5-HT3 receptor antagonist while lubazodone is also a 5-HT2A receptor antagonist.
Fluoxetine was introduced in 1987 and was the first major SSRI to be marketed.
A study examining publication of results from FDA-evaluated antidepressants concluded that those with favorable results were much more likely to be published than those with negative results. Furthermore, an investigation of 185 meta-analyses on antidepressants found that 79% of them had authors affiliated in some way to pharmaceutical companies and that they were reluctant to report caveats for antidepressants.
David Healy has argued that warning signs were available for many years prior to regulatory authorities moving to put warnings on antidepressant labels that they might cause suicidal thoughts. At the time these warnings were added, others argued that the evidence for harm remained unpersuasive and others continued to do so after the warnings were added.
In other organisms
SSRIs are common environmental contaminant findings near human settlement.
- List of antidepressants
- Serotonin releasing agent
- Serotonin–norepinephrine reuptake inhibitor
- ↑ "Chapter 7: Mood Disorders and Suicide". Abnormal Psychology: An Integrative Approach (Fifth ed.). Belmont, CA: Wadsworth Cengage Learning. 2009. p. 239. ISBN 978-0495095569. OCLC 192055408.
- ↑ "Mechanism of Action of Antidepressants". Psychopharmacology Bulletin 36. Summer 2002. http://pdfs.semanticscholar.org/9848/def34903ad758ec8de1b81c31b603644b396.pdf.
- ↑ "Selective Serotonin Reuptake Inhibitors". Antidepressants: Past, Present and Future. Berlin: Springer. 2004. pp. 241–262. ISBN 978-3540430544. https://books.google.com/books?id=sO_hArhCxwMC&pg=PA241.
- ↑ Psychology today: Depression and Serotonin: What the New Review Actually Says
- ↑ Kramer, Peter (7 Sep 2011). "In Defense of Antidepressants". The New York Times. https://www.nytimes.com/2011/07/10/opinion/sunday/10antidepressants.html.
- ↑ 6.0 6.1 "Antidepressant drug effects and depression severity: a patient-level meta-analysis". JAMA 303 (1): 47–53. January 2010. doi:10.1001/jama.2009.1943. PMID 20051569.
- ↑ "Antidepressants work, sort of – our system of care does not". Journal of Clinical Psychopharmacology 30 (2): 101–104. April 2010. doi:10.1097/JCP.0b013e3181d52dea. PMID 20520282. https://zenodo.org/record/890741.
- ↑ 8.0 8.1 "Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis". BMC Psychiatry 17 (1): 58. February 2017. doi:10.1186/s12888-016-1173-2. PMID 28178949.
- ↑ "Understanding and treating depersonalisation disorder". Advances in Psychiatric Treatment 11 (2): 92–100. 2005. doi:10.1192/apt.11.2.92.
- ↑ 10.0 10.1 National Collaborating Centre for Mental Health (October 2009). "Depression Quick Reference Guide". The National Institute for Health and Care Excellence (NICE). http://www.nice.org.uk/nicemedia/pdf/CG%2090%20QRG%20LR%20FINAL.pdf.
- ↑ 11.0 11.1 "Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration". PLOS Medicine 5 (2): e45. February 2008. doi:10.1371/journal.pmed.0050045. PMID 18303940.
- ↑ "Placebo, Prozac and PLoS: significant lessons for psychopharmacology". Journal of Psychopharmacology 25 (10): 1277–1288. June 2010. doi:10.1177/0269881110372544. PMID 20571143.
- ↑ "Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data". The International Journal of Neuropsychopharmacology 14 (3): 405–412. August 2010. doi:10.1017/S1461145710000957. PMID 20800012.
- ↑ "Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine". Archives of General Psychiatry 69 (6): 572–579. June 2012. doi:10.1001/archgenpsychiatry.2011.2044. PMID 22393205.
- ↑ "Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective". Acta Neuropsychiatrica 30 (5): 244–250. 2018. doi:10.1017/neu.2017.23. PMID 28718394.
- ↑ "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet 391 (10128): 1357–1366. April 2018. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251.
- ↑ "New generation antidepressants for depression in children and adolescents: a network meta-analysis". The Cochrane Database of Systematic Reviews 2021 (5): CD013674. May 2021. doi:10.1002/14651858.CD013674.pub2. PMID 34029378.
- ↑ "Depression in children and young people: identification and management". The National Institute for Health and Care Excellence (NICE). June 2019. http://www.nice.org.uk/guidance/ng134.
- ↑ Canton, John; Scott, Kate M; Glue, Paul (2012). "Optimal treatment of social phobia: systematic review and meta-analysis". Neuropsychiatric Disease and Treatment 8: 203–215. doi:10.2147/NDT.S23317. ISSN 1176-6328. PMID 22665997.
- ↑ Alexander, Walter (January 2012). "Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans". Pharmacy and Therapeutics 37 (1): 32–38. ISSN 1052-1372. PMID 22346334.
- ↑ 21.0 21.1 "www.nice.org.uk". http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf.
- ↑ Katzman, Martin A; Bleau, Pierre; Blier, Pierre; Chokka, Pratap; Kjernisted, Kevin; Van Ameringen, Michael (2014-07-02). "Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders". BMC Psychiatry 14 (Suppl 1): S1. doi:10.1186/1471-244X-14-S1-S1. ISSN 1471-244X. PMID 25081580.
- ↑ "Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder". November 2005. http://www.nice.org.uk/nicemedia/pdf/cg031niceguideline.pdf.
- ↑ Arroll, Bruce, ed (July 2009). "Antidepressants versus placebo for depression in primary care". The Cochrane Database of Systematic Reviews 2009 (3): CD007954. doi:10.1002/14651858.CD007954. PMID 19588448. https://discovery.dundee.ac.uk/en/publications/85b92403-d474-4e5a-b606-65f7e0f86575.
- ↑ Busko, Marlene (28 February 2008). "Review Finds SSRIs Modestly Effective in Short-Term Treatment of OCD". http://www.medscape.com/viewarticle/570825+.
- ↑ "Evidence-based pharmacotherapy of obsessive-compulsive disorder". The International Journal of Neuropsychopharmacology 15 (8): 1173–1191. 2012. doi:10.1017/S1461145711001829. PMID 22226028. http://uhra.herts.ac.uk/bitstream/2299/216/1/900276.pdf.
- ↑ "Sertraline prescribing information". http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019839s070,020990s032lbl.pdf.
- ↑ "Paroxetine prescribing information". https://www.apotex.com/us/en/products/downloads/pil/paxil_irtb_ins.pdf.
- ↑ Batelaan, Neeltje M.; Van Balkom, Anton J. L. M.; Stein, Dan J. (2012-04-01). "Evidence-based pharmacotherapy of panic disorder: an update" (in en). International Journal of Neuropsychopharmacology 15 (3): 403–415. doi:10.1017/S1461145711000800. ISSN 1461-1457. PMID 21733234.
- ↑ Asnis, G. M.; Hameedi, F. A.; Goddard, A. W.; Potkin, S. G.; Black, D.; Jameel, M.; Desagani, K.; Woods, S. W. (2001-08-05). "Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients". Psychiatry Research 103 (1): 1–14. doi:10.1016/s0165-1781(01)00265-7. ISSN 0165-1781. PMID 11472786.
- ↑ Bighelli, I.; Castellazzi, M.; Cipriani, A.; Girlanda, F.; Guaiana, G.; Koesters, M.; Turrini, G.; Furukawa, T. A. et al. (2018). "Antidepressants for panic disorder in adults" (in en). The Cochrane Database of Systematic Reviews 2018 (4): CD010676. doi:10.1002/14651858.CD010676.pub2. PMID 29620793. PMC 6494573. https://www.cochrane.org/CD010676/DEPRESSN_antidepressants-panic-disorder-adults. Retrieved 2020-03-14.
- ↑ 32.0 32.1 32.2 "Eating disorders in over 8s: management". The National Institute for Health and Care Excellence (NICE). January 2004. http://www.nice.org.uk/nicemedia/pdf/CG9FullGuideline.pdf.
- ↑ 33.0 33.1 "Practice guideline for the treatment of patients with eating disorders". U.S. Department of Health and Human Services. http://www.guidelines.gov/content.aspx?id=9318+.
- ↑ "Evidence-based pharmacotherapy of eating disorders". The International Journal of Neuropsychopharmacology 15 (2): 189–207. March 2012. doi:10.1017/S1461145711000381. PMID 21414249.
- ↑ Legg, Lynn A.; Tilney, Russel; Hsieh, Cheng-Fang; Wu, Simiao; Lundström, Erik; Rudberg, Ann-Sofie; Kutlubaev, Mansur A.; Dennis, Martin et al. (26 November 2019). "Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery". The Cochrane Database of Systematic Reviews 2019 (11). doi:10.1002/14651858.CD009286.pub3. ISSN 1469-493X. PMID 31769878.
- ↑ Waldinger MD (November 2007). "Premature ejaculation: state of the art". The Urologic Clinics of North America 34 (4): 591–599, vii–viii. doi:10.1016/j.ucl.2007.08.011. PMID 17983899.
- ↑ Machado-Vieira; Baumann; Wheeler-Castillo; Latov; Henter; Salvadore; Zarate (January 2010). "The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments". Pharmaceuticals 3 (1): 19–41. doi:10.3390/ph3010019. PMID 27713241.
- ↑ Higgins; Nash; Lynch (September 2010). "Antidepressant-associated sexual dysfunction: impact, effects, and treatment". Drug Healthc Patient Saf 2: 141–150. doi:10.2147/DHPS.S7634. PMID 21701626.
- ↑ "Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review". Behavioral Sciences 9 (5): 57. May 2019. doi:10.3390/bs9050057. PMID 31126061.
- ↑ Wu Q, Bencaz AF, Hentz JG, Crowell MD (January 2012). "Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies". Osteoporosis International 23 (1): 365–375. doi:10.1007/s00198-011-1778-8. PMID 21904950.
- ↑ Stahl SM, Lonnen AJ (2011). "The Mechanism of Drug-induced Akathsia". CNS Spectrums. PMID 21406165.
- ↑ Lane RM (1998). "SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment". Journal of Psychopharmacology 12 (2): 192–214. doi:10.1177/026988119801200212. PMID 9694033.
- ↑ Koliscak LP, Makela EH (2009). "Selective serotonin reuptake inhibitor-induced akathisia". Journal of the American Pharmacists Association 49 (2): e28–36; quiz e37–38. doi:10.1331/JAPhA.2009.08083. PMID 19289334.
- ↑ Leo RJ (1996). "Movement disorders associated with the serotonin selective reuptake inhibitors". The Journal of Clinical Psychiatry 57 (10): 449–454. doi:10.4088/jcp.v57n1002. PMID 8909330.
- ↑ 45.0 45.1 Bahrick, Audrey S. (2008). "Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence". The Open Psychology Journal 1: 42–50. doi:10.2174/1874350100801010042. https://benthamopen.com/ABSTRACT/TOPSYJ-1-42.
- ↑ "Strategies for managing sexual dysfunction induced by antidepressant medication". The Cochrane Database of Systematic Reviews 5 (5): CD003382. May 2013. doi:10.1002/14651858.CD003382.pub3. PMID 23728643. https://kclpure.kcl.ac.uk/portal/en/publications/strategies-for-managing-sexual-dysfunction-induced-by-antidepressant-medication(5f0f0033-e139-42cc-9590-d3b5cad1bb25).html.
- ↑ 47.0 47.1 Bahrick, AS (2006). "Post SSRI sexual dysfunction". American Society for the Advancement of Pharmacotherapy Tablet 7.3: 2–3. https://www.researchgate.net/publication/236587031.
- ↑ Zajecka, J.; Mitchell, S.; Fawcett, J. (1997). "Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory". Psychopharmacology Bulletin 33 (4): 755–760. ISSN 0048-5764. PMID 9493488. https://pubmed.ncbi.nlm.nih.gov/9493488. "Males and females were found to experience similar rates of treatment emergent sexual dysfunction at 60 percent and 57 percent, respectively.".
- ↑ 49.0 49.1 "Sexual Consequences of Post-SSRI Syndrome". Sexual Medicine Reviews 5 (4): 429–433. October 2017. doi:10.1016/j.sxmr.2017.05.002. PMID 28642048. "Initial SSRI registration studies found that such side effects were reported by fewer than 10% of patients. When doctors specifically asked about treatment-emergent sexual difficulties, some found that they were present in up to 70% of patients.".
- ↑ 50.0 50.1 Healy, David (2020). "Post-SSRI sexual dysfunction & other enduring sexual dysfunctions". Epidemiology and Psychiatric Sciences 29: e55. doi:10.1017/S2045796019000519. PMID 31543091. "Close to 100% of takers of a selective serotonin reuptake inhibitor (SSRI) have a degree of genital sensory change within 30 min of taking.".
- ↑ "Sexual dysfunction, depression, and the impact of antidepressants". Journal of Clinical Psychopharmacology 29 (2): 157–164. April 2009. doi:10.1097/jcp.0b013e31819c76e9. PMID 19512977.
- ↑ "Psychiatric disorders and sexual dysfunction". Neurology of Sexual and Bladder Disorders. Handbook of Clinical Neurology. 130. 2015. pp. 479–83. doi:10.1016/B978-0-444-63247-0.00027-4. ISBN 978-0444632470.
- ↑ "Prozac Highlights of Prescribing Information". Eli Lilly and Company. 24 March 2017. http://pi.lilly.com/us/prozac.pdf.
- ↑ American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington: American Psychiatric Publishing. pp. 449. ISBN 978-0890425558.
- ↑ Pharmacovigilance Risk Assessment Committee (PRAC) (11 June 2019). "New product information wording – Extracts from PRAC recommendations on signals". European Medicines Agency. https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_en.pdf#page=2.
- ↑ "Minutes of PRAC meeting of 13–16 May 2019: Signal of persistent sexual dysfunction after drug withdrawal". 14 June 2019. https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-may-2019_en.pdf#page=25.
- ↑ "Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches". The Journal of Clinical Psychiatry 55 (9): 406–413. September 1994. PMID 7929021.
- ↑ Balon R (2006). "SSRI-Associated Sexual Dysfunction". The American Journal of Psychiatry 163 (9): 1504–1509; quiz 1664. doi:10.1176/appi.ajp.163.9.1504. PMID 16946173.
- ↑ Serretti, Alessandro (2009). "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". J Clin Psychopharmacol 29 (3): 259–266. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. http://doi.org/10.1097/JCP.0b013e3181a5233f. Retrieved 2022-05-23.
- ↑ Clayton, Anita H. (2003). "Antidepressant-Associated Sexual Dysfunction: A Potentially Avoidable Therapeutic Challenge". Primary Psychiatry 10 (1): 55–61. http://www.primarypsychiatry.com/aspx/articledetail.aspx?articleid=1362. Retrieved 2013-02-19.
- ↑ "Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction". Current Women's Health Reports 2 (6): 409–416. December 2002. PMID 12429073.
- ↑ "Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation". International Journal of Impotence Research 24 (5): 171–173. September 2012. doi:10.1038/ijir.2012.12. PMID 22573230.
- ↑ Scherzer, Nikolas D.; Reddy, Amit G.; Le, Tan V.; Chernobylsky, David; Hellstrom, Wayne J.G. (April 2019). "Unintended Consequences: A Review of Pharmacologically-Induced Priapism". Sexual Medicine Reviews 7 (2): 283–292. doi:10.1016/j.sxmr.2018.09.002. PMID 30503727.
- ↑ "Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs". Clin Neuropsychiatry 16 (2): 75–85. April 2019. PMID 34908941.
- ↑ 65.0 65.1 65.2 65.3 "Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research". Front Psychiatry 12: 792960. 2021. doi:10.3389/fpsyt.2021.792960. PMID 34970173.
- ↑ "SSRI-induced apathy syndrome: a clinical review". J Psychiatr Pract 10 (3): 196–199. May 2004. doi:10.1097/00131746-200405000-00010. PMID 15330228.
- ↑ "SSRI-Induced Indifference". Psychiatry (Edgmont) 7 (10): 14–18. October 2010. PMID 21103140.
- ↑ "Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study". Br J Psychiatry 195 (3): 211–217. September 2009. doi:10.1192/bjp.bp.108.051110. PMID 19721109.
- ↑ "Emotional blunting with antidepressant treatments: A survey among depressed patients". J Affect Disord 221: 31–35. October 2017. doi:10.1016/j.jad.2017.05.048. PMID 28628765. https://ora.ox.ac.uk/objects/uuid:8a7067a3-7b21-481f-ac80-32f1929d3ff7.
- ↑ "Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects". Curr Drug Saf 13 (3): 176–186. 2018. doi:10.2174/1574886313666180605095130. PMID 29866014. http://roar.uel.ac.uk/7564/1/7564.pdf.
- ↑ 71.0 71.1 "Are all antidepressants the same? The consumer has a point". Psychol Med: 1–8. March 2022. doi:10.1017/S0033291722000678. PMID 35346413.
- ↑ "Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents". J Child Adolesc Psychopharmacol 11 (2): 181–186. 2001. doi:10.1089/104454601750284090. PMID 11436958.
- ↑ "Antidepressants: misnamed and misrepresented". World Psychiatry 14 (3): 302–303. October 2015. doi:10.1002/wps.20243. PMID 26407780.
- ↑ "Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial". Int J Neuropsychopharmacol 16 (10): 2219–2234. November 2013. doi:10.1017/S1461145713000679. PMID 23823799.
- ↑ "Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment". J Affect Disord 283: 472–479. March 2021. doi:10.1016/j.jad.2020.11.106. PMID 33516560.
- ↑ "Antidepressants and violence: problems at the interface of medicine and law". PLOS Medicine 3 (9): e372. September 2006. doi:10.1371/journal.pmed.0030372. PMID 16968128.
- ↑ Breggin, Peter R.; Breggin, Ginger Ross (1995). Talking Back to Prozac. Macmillan Publishers. p. 154. ISBN 978-0312956066. https://archive.org/details/talkingbacktopro00pete/page/154.
- ↑ Costagliola; Parmeggiani; Semeraro; Sebastiani (December 2008). "Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure.". Current Neuropharmacology 6 (4): 293–310. doi:10.2174/157015908787386104. PMID 19587851.
- ↑ Lochhead, J (September 2015). "SSRI-associated optic neuropathy.". Eye 29 (9): 1233–1235. doi:10.1038/eye.2015.119. PMID 26139049.
- ↑ "Antidepressant Use and Risk of Coronary Heart Disease: Meta-Analysis of Observational Studies". British Journal of Clinical Pharmacology 78 (4): 727–737. Mar 20, 2014. doi:10.1111/bcp.12383. PMID 24646010.
- ↑ "Antidepressant Use in Pregnancy and the Risk of Cardiac Defects". New England Journal of Medicine 370 (25): 2397–2407. 2014. doi:10.1056/NEJMoa1312828. PMID 24941178.
- ↑ Goldberg RJ (1998). "Selective serotonin reuptake inhibitors: infrequent medical adverse effects". Archives of Family Medicine 7 (1): 78–84. doi:10.1001/archfami.7.1.78. PMID 9443704.
- ↑ FDA (December 2018). "FDA Drug Safety". FDA. https://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.
- ↑ Citalopram and escitalopram: QT interval prolongation – new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. From Medicines and Healthcare products Regulatory Agency. Article date: December 2011
- ↑ "Clinical and ECG Effects of Escitalopram Overdose". http://m.utoledo.edu/med/gme/em/pdfs/ECG_escitalopram.pdf.
- ↑ "Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?". Current Medicinal Chemistry 6 (6): 469–480. Jun 1999. doi:10.2174/0929867306666220330184544. PMID 10213794.
- ↑ Andrade; Sharma (September 2016). "Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding.". The Psychiatric Clinics of North America 39 (3): 413–426. doi:10.1016/j.psc.2016.04.010. PMID 27514297.
- ↑ 88.0 88.1 "Selective serotonin re-uptake inhibitors and the risk of bleeding". Expert Opinion on Drug Safety 4 (2): 337–344. March 2005. doi:10.1517/147403184.108.40.2067. PMID 15794724.
- ↑ 89.0 89.1 The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. 2012. ISBN 978-0470979693.
- ↑ "Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding: A Review for Clinicians and a Reconsideration of Mechanisms". The Journal of Clinical Psychiatry 71 (12): 1565–1575. December 2010. doi:10.4088/JCP.09r05786blu. PMID 21190637.
- ↑ 91.0 91.1 "Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents". Archives of General Psychiatry 65 (7): 795–803. July 2008. doi:10.1001/archpsyc.65.7.795. PMID 18606952.
- ↑ "Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis". Neurology 79 (18): 1862–1865. 2012. doi:10.1212/WNL.0b013e318271f848. PMID 23077009. https://semanticscholar.org/paper/b6f8165047aae29d2b0e279cbb5e3f268c2863cd.
- ↑ Serebruany VL (February 2006). "Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?". The American Journal of Medicine 119 (2): 113–116. doi:10.1016/j.amjmed.2005.03.044. PMID 16443409.
- ↑ "Influence of antidepressants on hemostasis". Dialogues in Clinical Neuroscience 9 (1): 47–59. 2007. doi:10.31887/DCNS.2007.9.1/dhalperin. PMID 17506225.
- ↑ "Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms". The Journal of Clinical Psychiatry 71 (12): 1565–1575. 2010. doi:10.4088/JCP.09r05786blu. PMID 21190637.
- ↑ de Abajo FJ (2011). "Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients". Drugs & Aging 28 (5): 345–367. doi:10.2165/11589340-000000000-00000. PMID 21542658.
- ↑ "Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis". Journal of Bone and Mineral Research 27 (5): 1186–1195. May 2012. doi:10.1002/jbmr.1554. PMID 22258738.
- ↑ "Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome". Endocrine 48 (1): 65–68. February 2015. doi:10.1007/s12020-014-0357-0. PMID 25091520. https://zenodo.org/record/845248.
- ↑ "Drugs that may harm bone: Mitigating the risk". Cleveland Clinic Journal of Medicine 83 (4): 281–288. April 2016. doi:10.3949/ccjm.83a.15066. PMID 27055202.
- ↑ "Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression". Drugs & Aging 33 (1): 21–25. January 2016. doi:10.1007/s40266-015-0323-4. PMID 26547857.
- ↑ "Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications". The Annals of Pharmacotherapy 49 (4): 437–447. April 2015. doi:10.1177/1060028015569594. PMID 25667198.
- ↑ 102.0 102.1 "Do Selective Serotonin Reuptake Inhibitors (SSRIs) Cause Fractures?". Current Osteoporosis Reports 14 (5): 211–218. October 2016. doi:10.1007/s11914-016-0322-3. PMID 27495351.
- ↑ "Changes in volumetric BMD of radius and tibia upon antidepressant drug administration in young depressive patients". Journal of Musculoskeletal & Neuronal Interactions 12 (4): 224–229. December 2012. PMID 23196265.
- ↑ Garrett, A. R.; Hawley, J. S. (2018). "SSRI-associated bruxism: A systematic review of published case reports.". Neurology. Clinical Practice 8 (2): 135–141. doi:10.1212/CPJ.0000000000000433. ISSN 2163-0402. PMID 29708207.
- ↑ Prisco, V.; Iannaccone, T.; Di Grezia, G. (2017-04-01). "Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism" (in en). European Psychiatry. Abstract of the 25th European Congress of Psychiatry 41: S855. doi:10.1016/j.eurpsy.2017.01.1701. ISSN 0924-9338. http://www.sciencedirect.com/science/article/pii/S0924933817317169.
- ↑ Albayrak, Yakup; Ekinci, Okan (2011). "Duloxetine-induced nocturnal bruxism resolved by buspirone: case report". Clinical Neuropharmacology 34 (4): 137–138. doi:10.1097/WNF.0b013e3182227736. ISSN 1537-162X. PMID 21768799.
- ↑ "Serotonin syndrome". The Ochsner Journal 13 (4): 533–540. 2013. PMID 24358002.
- ↑ "The serotonin syndrome". The New England Journal of Medicine 352 (11): 1112–1120. March 2005. doi:10.1056/nejmra041867. PMID 15784664. https://semanticscholar.org/paper/bd6134bea06b830b36b696ffd7b34b395f6f72ec.
- ↑ "Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome". JAMA Neurology 75 (5): 566–572. May 2018. doi:10.1001/jamaneurol.2017.5144. PMID 29482205.
- ↑ Ferri, Fred F. (2016) (in en). Ferri's Clinical Advisor 2017: 5 Books in 1. Elsevier Health Sciences. pp. 1154–1155. ISBN 978-0323448383. https://books.google.com/books?id=rRhCDAAAQBAJ&pg=PA1154.
- ↑ 111.0 111.1 "Clinical review: relationship between antidepressant drugs and suicidal behavior in adults". FDA. 2006-11-17. pp. 11–74. https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf.
- ↑ "Statistical Evaluation of Suicidality in Adults Treated with Antidepressants". FDA. 2006-11-17. pp. 75–140. https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf.
- ↑ "Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study". Archives of General Psychiatry 63 (8): 865–872. August 2006. doi:10.1001/archpsyc.63.8.865. PMID 16894062.
- ↑ "Review and evaluation of clinical data. Relationship between psychiatric drugs and pediatric suicidal behavior". FDA. 2004-08-16. pp. 42, 115. https://www.fda.gov/OHRMS/DOCKETS/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf.
- ↑ "Antidepressant Use in Children, Adolescents, and Adults". U.S. Food and Drug Administration. https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm096273.
- ↑ "FDA Medication Guide for Antidepressants". https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088660.pdf%E2%80%8E.
- ↑ 117.0 117.1 "Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents". The Cochrane Database of Systematic Reviews 2014 (11): CD008324. November 2014. doi:10.1002/14651858.CD008324.pub3. PMID 25433518.
- ↑ "Overview | Depression in adults: recognition and management | Guidance | NICE". https://www.nice.org.uk/guidance/CG90.
- ↑ "Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo". Journal of Child and Adolescent Psychopharmacology 17 (5): 713–718. October 2007. doi:10.1089/cap.2006.0138. PMID 17979590.
- ↑ "The relationship between antidepressant prescription rates and rate of early adolescent suicide". The American Journal of Psychiatry 163 (11): 1898–1904. November 2006. doi:10.1176/appi.ajp.163.11.1898. PMID 17074941. https://semanticscholar.org/paper/144dac4ffee1c8e86f9d86c2112040d1f47f88fc.
- ↑ "Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants". MHRA. 2004-12-01. http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf.
- ↑ "Selective Serotonin Reuptake Inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data". MHRA. 2005-09-29. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019494.
- ↑ "Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review". BMJ 330 (7488): 385. February 2005. doi:10.1136/bmj.330.7488.385. PMID 15718537.
- ↑ "Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials". BMJ 330 (7488): 396. February 2005. doi:10.1136/bmj.330.7488.396. PMID 15718539.
- ↑ "Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries". Journal of Affective Disorders 94 (1–3): 3–13. August 2006. doi:10.1016/j.jad.2006.04.003. PMID 16712945.
- ↑ "How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?". The Australian and New Zealand Journal of Psychiatry 40 (11–12): 941–950. 2006. doi:10.1111/j.1440-1614.2006.01917.x. PMID 17054562.
- ↑ "Ten years after the FDA black box warning for antidepressant drugs: A critical narrative review". Archives of Clinical Psychiatry 43 (3): 60–66. 2016. doi:10.1590/0101-60830000000086.
- ↑ 128.0 128.1 "The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis". Psychother Psychosom 86 (5): 268–282. 2017. doi:10.1159/000477940. PMID 28903117.
- ↑ "Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome". Therapeutic Drug Monitoring 34 (6): 607–614. December 2012. doi:10.1097/FTD.0b013e31826d07ea. PMID 23042258.
- ↑ "Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials". Reproductive Toxicology 22 (4): 571–575. 2006. doi:10.1016/j.reprotox.2006.03.019. PMID 16720091.
- ↑ 131.0 131.1 "Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis". Daru 20 (1): 75. 2012. doi:10.1186/2008-2231-20-75. PMID 23351929.
- ↑ "Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis". BJOG 123 (12): 1900–1907. November 2016. doi:10.1111/1471-0528.14144. PMID 27239775.
- ↑ "Do findings differ across research design? The case of antidepressant use in pregnancy and malformations". Journal of Population Therapeutics and Clinical Pharmacology 19 (2): e334–348. 2012. PMID 22946124.
- ↑ "The fetal safety of fluoxetine: a systematic review and meta-analysis". Journal of Obstetrics and Gynaecology Canada 35 (4): 362–369. April 2013. doi:10.1016/S1701-2163(15)30965-8. PMID 23660045.
- ↑ "Selective serotonin reuptake inhibitors and malformations: case closed?". Seminars in Fetal & Neonatal Medicine 18 (1): 19–22. February 2013. doi:10.1016/j.siny.2012.10.004. PMID 23228547.
- ↑ "Breastfeeding Update: SDCBC's quarterly newsletter". Breastfeeding.org. http://www.breastfeeding.org/newsletter/v2i4/page2.html.
- ↑ "Using Antidepressants in Breastfeeding Mothers". kellymom.com. http://www.kellymom.com/health/meds/antidepressants-hale10-02.html.
- ↑ "SSRIs during breastfeeding: spotlight on milk-to-plasma ratio". Archives of Women's Mental Health 10 (2): 39–51. 2007. doi:10.1007/s00737-007-0173-0. PMID 17294355.
- ↑ "Paediatric outcomes following intrauterine exposure to serotonin reuptake inhibitors: a systematic review". Danish Medical Bulletin 58 (9): A4303. September 2011. PMID 21893008.
- ↑ "The use of psychotropic medication during pregnancy: how about the newborn?". Neuropsychiatric Disease and Treatment 9: 1257–1266. 2013. doi:10.2147/NDT.S36394. PMID 24039427.
- ↑ Persistent Newborn Pulmonary Hypertension at eMedicine
- ↑ "Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis". BMJ 348: f6932. 2014. doi:10.1136/bmj.f6932. PMID 24429387.
- ↑ "Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review". Reproductive Toxicology 34 (3): 293–297. November 2012. doi:10.1016/j.reprotox.2012.04.015. PMID 22564982.
- ↑ "Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods?". Journal of Affective Disorders 182: 132–137. August 2015. doi:10.1016/j.jad.2015.04.048. PMID 25985383.
- ↑ "Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism". The New England Journal of Medicine 369 (25): 2406–2415. December 2013. doi:10.1056/NEJMoa1301449. PMID 24350950. https://semanticscholar.org/paper/721cc4b44f103b00ad37669012e4047a350e7154.
- ↑ 146.0 146.1 "Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study". Journal of the American Academy of Child and Adolescent Psychiatry 55 (5): 359–366. May 2016. doi:10.1016/j.jaac.2016.02.013. PMID 27126849.
- ↑ Gitlin, Michael J. (2018-12-01). "Antidepressants in bipolar depression: an enduring controversy". International Journal of Bipolar Disorders 6 (1): 25. doi:10.1186/s40345-018-0133-9. ISSN 2194-7511. PMID 30506151.
- ↑ Viktorin, Alexander; Lichtenstein, Paul; Thase, Michael E.; Larsson, Henrik; Lundholm, Cecilia; Magnusson, Patrik K. E.; Landén, Mikael (2014). "The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer". The American Journal of Psychiatry 171 (10): 1067–1073. doi:10.1176/appi.ajp.2014.13111501. ISSN 1535-7228. PMID 24935197. https://semanticscholar.org/paper/bb8bce981c025f4365aa4950c5107d99d13af988.
- ↑ "Complications of SSRI Treatment". Journal of Child and Adolescent Psychopharmacology 11 (1): 1–4. 2001. doi:10.1089/104454601750143320. PMID 11322738.
- ↑ "Serotonin syndrome and other serotonergic disorders". Pain Medicine 4 (1): 63–74. March 2003. doi:10.1046/j.1526-4637.2003.03005.x. PMID 12873279.
- ↑ "The serotonin syndrome". The New England Journal of Medicine 352 (11): 1112–1120. March 2005. doi:10.1056/NEJMra041867. PMID 15784664. https://semanticscholar.org/paper/bd6134bea06b830b36b696ffd7b34b395f6f72ec.
- ↑ "Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans". Proceedings of the National Academy of Sciences of the United States of America 108 (22): 9262–9267. May 2011. doi:10.1073/pnas.1104836108. PMID 21518864.
- ↑ Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). McGraw Hill Professional. 2010. ISBN 978-0071624428.
- ↑ Ciraulo, Domenic A; Shader, Richard Irwin, eds (2011). Pharmacotherapy of Depression (2nd ed.). Springer. p. 49. doi:10.1007/978-1-60327-435-7. ISBN 978-1603274357. https://archive.org/details/pharmacotherapyd00cira.
- ↑ "Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine". European Journal of Clinical Pharmacology 51 (1): 73–78. 1996. doi:10.1007/s002280050163. PMID 8880055.
- ↑ "Opioid pharmacokinetic drug-drug interactions". The American Journal of Managed Care 17 (Suppl 11): S276–287. September 2011. PMID 21999760. https://www.ajmc.com/pubMed.php?pii=51946.
- ↑ "Paroxetine hydrochloride – Drug Summary". Physicians' Desk Reference, LLC. https://www.pdr.net/drug-summary/Paxil-paroxetine-hydrochloride-215.2678.
- ↑ "Opioid metabolism". Mayo Clinic Proceedings 84 (7): 613–624. July 2009. doi:10.4065/84.7.613. PMID 19567715.
- ↑ "Immunisation and pregnancy – who, what, when and why?". Australian Prescriber 40 (4): 122–124. August 2017. doi:10.18773/austprescr.2017.046. PMID 28947846.
- ↑ "New FDA black box warning for codeine: how will this affect dentists?". Anesthesia Progress 60 (2): 35–36. 2013. doi:10.2344/0003-3006-60.2.35. PMID 23763556.
- ↑ "Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study". BMJ 340: c693. February 2010. doi:10.1136/bmj.c693. PMID 20142325.
- ↑ 162.0 162.1 162.2 "Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose". Journal of Toxicology. Clinical Toxicology 42 (3): 277–285. 2004. doi:10.1081/CLT-120037428. PMID 15362595.
- ↑ "Acute fluoxetine overdose: a report of 234 cases". The American Journal of Emergency Medicine 10 (2): 115–120. 1992. doi:10.1016/0735-6757(92)90041-U. PMID 1586402.
- ↑ "Fatal overdose with citalopram". Lancet 348 (9023): 339–340. 1996. doi:10.1016/S0140-6736(05)64513-8. PMID 8709713.
- ↑ "The serotonin syndrome. Implicated drugs, pathophysiology and management". Drug Safety 13 (2): 94–104. August 1995. doi:10.2165/00002018-199513020-00004. PMID 7576268.
- ↑ Gupta, Ramesh (2012) (in English). Veterinary Toxicology : Basic and Clinical Principles (2 ed.). Boston: Academic Press. pp. xii + 1438. ISBN 978-0-12-385926-6.
- ↑ 167.0 167.1 Gelenberg, Alan J.; Freeman, Marlene P.; Markowitz, John C.; Rosenbaum, Jerrold F.; Thase, Michael E.; Trivedi, Madhukar H.; Van Rhoads, Richard S. (October 2010). Practice Guideline for the Treatment of Patients With Major Depressive Disorder (third ed.). American Psychiatric Association. ISBN 978-0890423387. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
- ↑ "Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved". Frontiers in Pharmacology 4: 45. 2013. doi:10.3389/fphar.2013.00045. PMID 23596418.
- ↑ Goodman, Louis Sanford; Brunton, Laurence L.; Chabner, Bruce; Knollmann, Björn C. (2001). Goodman and Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill. pp. 459–461. ISBN 978-0071624428.
- ↑ 170.0 170.1 Kolb, Bryan and Wishaw Ian. An Introduction to Brain and Behavior. New York: Worth Publishers 2006, Print.
- ↑ "P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents". Neuropsychopharmacology 38 (11): 2209–2219. October 2013. doi:10.1038/npp.2013.120. PMID 23670590.
- ↑ Shadfar, S.; Kim, Y. G.; Katila, N.; Neupane, S.; Ojha, U.; Bhurtel, S.; Srivastav, S.; Jeong, G. S. et al. (2018). "Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease". Molecular Neurobiology 55 (1): 554–566. doi:10.1007/s12035-016-0342-0. PMID 27975170. https://pubmed.ncbi.nlm.nih.gov/27975170/.
- ↑ 173.0 173.1 173.2 173.3 173.4 173.5 173.6 "Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered". Human Psychopharmacology 25 (3): 193–200. April 2010. doi:10.1002/hup.1106. PMID 20373470.
- ↑ 174.0 174.1 174.2 174.3 174.4 174.5 174.6 "Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders". Sigma Receptors: Their Role in Disease and as Therapeutic Targets. 964. 2017. 153–161. doi:10.1007/978-3-319-50174-1_11. ISBN 978-3319501727.
- ↑ "The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report". Annals of General Psychiatry 9: 23. May 2010. doi:10.1186/1744-859X-9-23. PMID 20492642.
- ↑ "Separation of ascorbic acid and 2-keto-L-gulonic acid". Current Neuropharmacology 61 (8): 1333–1334. August 1972. doi:10.2174/1570159X14666151208113700. PMID 27640518.
- ↑ "The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants". Journal of Psychopharmacology 30 (1): 13–22. January 2016. doi:10.1177/0269881115609072. PMID 26464458.
- ↑ "Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis". Molecular Neurobiology 55 (5): 4195–4206. May 2018. doi:10.1007/s12035-017-0632-1. PMID 28612257. https://kclpure.kcl.ac.uk/portal/en/publications/peripheral-alterations-in-cytokine-and-chemokine-levels-after-antidepressant-drug-treatment-for-major-depressive-disorder(7fb3d49a-30e3-4cfd-9a1c-df003daf8dad).html.
- ↑ "Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis". Progress in Neuro-Psychopharmacology & Biological Psychiatry 80 (Pt C): 217–226. January 2018. doi:10.1016/j.pnpbp.2017.04.026. PMID 28445690.
- ↑ "Association of depressive disorders, depression characteristics and antidepressant medication with inflammation". Translational Psychiatry 2 (2): e79. February 2012. doi:10.1038/tp.2012.8. PMID 22832816.
- ↑ 181.0 181.1 "Antidepressant therapies inhibit inflammation and microglial M1-polarization". Pharmacology & Therapeutics 163: 82–93. July 2016. doi:10.1016/j.pharmthera.2016.04.001. PMID 27101921.
- ↑ 182.0 182.1 "The role of macrophages in anti-inflammatory activity of antidepressant drugs". Immunobiology 222 (6): 823–830. June 2017. doi:10.1016/j.imbio.2016.07.001. PMID 27453459.
- ↑ 183.0 183.1 "Selective serotonin reuptake inhibitors as a novel class of immunosuppressants". International Immunopharmacology 20 (1): 148–156. May 2014. doi:10.1016/j.intimp.2014.02.030. PMID 24613205.
- ↑ Kang, Peter B.; Draper, Isabelle; Alexander, Matthew S.; Wagner, Richard E.; Pacak, Christina A.; Chahin, Nizar; Berg, Jonathan S.; Finkel, Richard S. et al. (2019). "Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy". Human Molecular Genetics 28 (14): 2365–2377. doi:10.1093/hmg/ddz064. PMID 31267131.
- ↑ "Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils". Depression and Anxiety 24 (5): 350–357. 2007. doi:10.1002/da.20251. PMID 17096399.
- ↑ "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability". Journal of Affective Disorders 58 (1): 19–36. April 2000. doi:10.1016/S0165-0327(99)00092-0. PMID 10760555.
- ↑ 187.0 187.1 187.2 187.3 "Serotonin norepinephrine reuptake inhibitors: similarities and differences". Primary Psychiatry 16 (4): 25. 2009. http://primarypsychiatry.com/serotonin-norepinephrine-reuptake-inhibitors-similarities-and-differences/.
- ↑ Montgomery, Stuart A. (July 2008). "Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants". CNS Spectrums 13 (7 Suppl 11): 27–33. doi:10.1017/s1092852900028297. ISSN 1092-8529. PMID 18622372.
- ↑ Waller, Derek G.; Sampson, Tony (2017). Medical Pharmacology and Therapeutics E-Book. Elsevier Health Sciences. pp. 302–. ISBN 978-0702071904. https://books.google.com/books?id=6b0tDwAAQBAJ&pg=PA302.
- ↑ Kornstein, Susan G.; Clayton, Anita H. (2010). Women's Mental Health, An Issue of Psychiatric Clinics – E-Book. Elsevier Health Sciences. pp. 389–. ISBN 978-1455700615. https://books.google.com/books?id=5jpHNa19jFUC&pg=PA389.
- ↑ "The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review". Current Neuropharmacology 14 (2): 191–199. 2016. doi:10.2174/1570159x14666151117122458. PMID 26572745.
- ↑ 192.0 192.1 "New-Generation, non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs". Current Medicinal Chemistry 24 (7): 772–792. 2018. doi:10.2174/0929867324666170712165042. PMID 28707591.
- ↑ 193.0 193.1 Ayd, Frank J. (2000). Lexicon of Psychiatry, Neurology, and the Neurosciences. Lippincott Williams & Wilkins. pp. 581–. ISBN 978-0781724685. https://books.google.com/books?id=ea_QVG2BFy8C&pg=PA581.
- ↑ 194.0 194.1 Progress in Drug Research. Birkhäuser. 2012. pp. 80–82. ISBN 978-3034883917. https://books.google.com/books?id=-d8FCAAAQBAJ&pg=PA80.
- ↑ 195.0 195.1 "Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century – a medicinal chemistry survey". Current Topics in Medicinal Chemistry 6 (17): 1801–1823. 2006. doi:10.2174/156802606778249810. PMID 17017959.
- ↑ 196.0 196.1 Haddad, Peter M. (1999). "Selective Serotonin Reuptake Inhibitors (SSRIs) Past, Present and Future. Edited by S. Clare Standford, R.G. Landes Company". Human Psychopharmacology: Clinical and Experimental (Austin, Texas) 15 (6): 471. doi:10.1002/1099-1077(200008)15:6<471::AID-HUP211>3.0.CO;2-4. ISBN 1570596492.
- ↑ "Selective publication of antidepressant trials and its influence on apparent efficacy". The New England Journal of Medicine 358 (3): 252–260. January 2008. doi:10.1056/NEJMsa065779. PMID 18199864.
- ↑ "Meta-analyses with industry involvement are massively published and report no caveats for antidepressants". Journal of Clinical Epidemiology 70: 155–163. February 2016. doi:10.1016/j.jclinepi.2015.08.021. PMID 26399904.
- ↑ "Antidepressant drug use & the risk of suicide". International Review of Psychiatry 17 (3): 163–172. June 2005. doi:10.1080/09540260500071624. PMID 16194787.
- ↑ "Suicidality with selective serotonin reuptake inhibitors: Valid claim?". Journal of Psychiatry & Neuroscience 28 (5): 340–347. September 2003. PMID 14517577.
- ↑ "Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports". The American Journal of Psychiatry 160 (4): 790–792. April 2003. doi:10.1176/appi.ajp.160.4.790. PMID 12668373. https://semanticscholar.org/paper/836ba5502baabb98ba0b0bbfe548f017d3c8af33.
- ↑ "Do antidepressants cause suicidality in children? A Bayesian meta-analysis". Clinical Trials 3 (2): 73–90; discussion 91–8. 2006. doi:10.1191/1740774506cn139oa. PMID 16773951.
- ↑ "Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine". Archives of General Psychiatry 69 (6): 580–587. June 2012. doi:10.1001/archgenpsychiatry.2011.2048. PMID 22309973.
- ↑ Christou, Anastasis; Papadavid, George; Dalias, Panagiotis; Fotopoulos, Vasileios; Michael, Costas; Bayona, Josep; Pina, Benjamin; Fatta, Despo (2019). "Ranking of crop plants according to their potential to uptake and accumulate contaminants of emerging concern". Environmental Research (Elsevier BV) 170: 422–432. doi:10.1016/j.envres.2018.12.048. ISSN 0013-9351. PMID 30623890. Bibcode: 2019ER....170..422C.
Original source: https://en.wikipedia.org/wiki/Selective serotonin reuptake inhibitor. Read more